GreenLight Biosciences Holdings (GRNA) Stock
GreenLight Biosciences Holdings is a biotechnology firm focused on developing and commercializing ribonucleic acid (RNA) solutions. Its innovative products serve both the human health and agricultural industries.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About GreenLight Biosciences Holdings
GreenLight Biosciences Holdings is a biotechnology firm focused on developing and commercializing ribonucleic acid (RNA) solutions. Its innovative products serve both the human health and agricultural industries. The company's human health portfolio includes mRNA vaccines and various therapeutic treatments, while its agricultural offerings feature RNA-based innovations designed to protect honeybees and defend crops. Established in 2008, GreenLight Biosciences Holdings is based in Medford, Massachusetts.
GreenLight Biosciences Holdings is headquartered in US.
GreenLight Biosciences Holdings (GRNA) stock trades at $0.30 with a market capitalization of $45.43M. The stock is valued at a price-to-earnings (P/E) ratio of -0.24, price-to-book of 0.82, price-to-sales of 7.12. Over the past 52 weeks the stock has ranged between $0.18 and $5.90, and currently trades 94.9% below its 52-week high.
On profitability, GreenLight Biosciences Holdings generates a return on equity (ROE) of -347.92%, return on capital employed of -145.01%, an operating margin of -2733.33%, a net profit margin of -2783.33%.
Official website: greenlightbiosciences.com